Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes."  The patent addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1).

https://www.biospace.com/article/releases/oramed-granted-u-s-combination-therapy-patent-for-oral-glp-1-and-amp-insulin-for-the-treatment-of-diabetes/